A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been ...

The trial evaluated Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex. A pre-specified interim ...

Back in late 2022, GSK pulled the multiple myeloma ADC Blenrep from the U.S. market merely days after announcing a phase 3 trial flop. The British pharma is now aiming to reintroduce the drug in ...

EU regulators have reportedly declined to recommend renewing conditional approval for GSK’s (NYSE:GSK) blood cancer drug Blenrep. According to Reuters, a European Medicines Agency committee has ...

2021 Blenrep (belantamab mafodotin-blmf) Adults patients with R/R MM who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an ...

Muhammed Atif from the BMCA said he was "gutted" by the incident. The damage the fire caused to building was "beyond our expectation", he added, and would stop the group's plan to open a community ...

Blenrep, a treatment for cancer, and asthma medicine Depemokimab are among the planned new launches. Nonetheless, shares in the company fell after it cut its outlook for its annual vaccines sales ...

We were particularly pleased to see the momentum now being established in our oncology business, and I'm delighted that we filed Blenrep in Europe, Japan, and the U.S. in the quarter. We also ...